No new efficacy numbers were disclosed, but Celcuity will present updated subgroup and safety results from the randomized Phase...

FibroBiologics has repaid all amounts outstanding under its Yorkville-issued convertible promissory notes, removing the prospect of further conversions into...

Tangram Therapeutics has submitted a Clinical Trial Application to the UK MHRA to begin a Phase 1/2 study of...

Tiziana Life SciencesLife Sciences’ intranasal anti-CD3 antibody, foralumab, has been accepted into the ALS MyMatch Program at the Healey...

BriaCell will present survival readouts from its Phase 2 study of the allogeneic whole cell vaccine Bria-IMT and new...

Macomics has validated its ENIGMAC macrophage discovery platform in antifibrotic biology, completing pooled and arrayed CRISPR-based gene modulation screens...

Junshi Biosciences reported that its Phase 3 JS001sc-002-III-NSCLC study met primary endpoints, showing non-inferior drug exposure for subcutaneous toripalimab...

In this interview, Vinita Navadgi, Sr. Director, Digital Patient Suite, IQVIA, shares a practical, thought-leading view on AI-driven electronic...

Gelteq reported a 38–45% increase in AUC and a markedly higher Cmax versus a marketed reference antihistamine in a...